ArticleHead & neck2025

Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti-PD-1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients.

Dan P Zandberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.